Upgrades and global expansion provide additional control, visibility, reliability and recovery for patient-critical, time-and temperature-sensitive products
Advancing to IND-enabling studies with multiple drug candidates
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
This acquisition is in line with Cipla's strategic imperative to augment the company's wellness portfolio for bringing about a shift from an illness to a wellness mindset.
The company plans to execute both these tenders at their API manufacturing unit located at Savli, Gujarat, India.
It includes both public and private health facilities including hospitals, clinics, diagnostic laboratories, and imaging centers
Medicines, including insulin, to be available in 40 lower-income countries
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
H Clinical is the leader in decentralized clinical trial support and home visits in Latin America
Subscribe To Our Newsletter & Stay Updated
